Why can’t I buy Roprestim/Romigrastim for injection?

Romiplostim/Romiplostim for injection (Romiplostim) is a drug used to treat specific types of thrombocytopenia, mainly in patients with chronic immune thrombocytopenia (ITP). ITP is an autoimmune disease in which the patient's immune system mistakenly attacks and destroys platelets, resulting in a reduced number of platelets and an increased risk of bleeding. Roprostim stimulates platelet production in the bone marrow, helping to increase platelet counts, thereby improving patients' bleeding symptoms and quality of life.

The mechanism of action of Roprostim is that it binds to the thrombopoietin receptor in the body, simulating the effect of natural thrombopoietin, thereby promoting the proliferation and maturation of megakaryocytes in the bone marrow and increasing the production of platelets. This drug is usually given to patients who have not responded well to conventional treatments, such as corticosteroids or immunosuppressants.

There may be several reasons why loplastin is difficult to purchase. First, the production and supply chain management of drugs are strictly regulated, and problems in any link may lead to drug shortages. In addition, pharmaceutical companies' distribution strategies in the market may also affect drug availability. If the demand for the drug exceeds production capacity, or due to a shortage of raw materials, the drug may not be supplied to the market in a timely manner.

Secondly, the drug’s marketing authorization and medical insurance reimbursement policies will also affect its market circulation. Some regions or countries may not have approved the use of Ropremilast, or even though it has been approved, it may not be covered by medical insurance, resulting in patients being unable to obtain the drug. In addition, the price of drugs is also a factor that cannot be ignored. In some areas with relatively limited economic conditions, high drug prices may become a barrier for patients to obtain treatment.